A Reversal for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Is Not Near. The Stock Has Rise in Shorts

June 20, 2017 - By Michael Collier

 A Reversal for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Is Not Near. The Stock Has Rise in Shorts

The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) registered an increase of 1.35% in short interest. ADMP’s total short interest was 2.97M shares in June as published by FINRA. Its up 1.35% from 2.93 million shares, reported previously. With 403,000 shares average volume, it will take short sellers 7 days to cover their ADMP’s short positions. The short interest to Adamis Pharmaceuticals Corporation’s float is 17.66%.

About 134,948 shares traded. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has declined 52.09% since June 20, 2016 and is downtrending. It has underperformed by 68.79% the S&P500.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The company has market cap of $130.84 million. The Firm is engaged in the development of its specialty pharmaceutical products. It currently has negative earnings. The Firm is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company .

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Ratings Coverage

Among 2 analysts covering Adamis Pharma (NASDAQ:ADMP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 3 analyst reports since December 1, 2015 according to SRatingsIntel. The stock of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has “Buy” rating given on Tuesday, December 1 by Maxim Group. Maxim Group maintained Adamis Pharmaceuticals Corp (NASDAQ:ADMP) rating on Thursday, July 21. Maxim Group has “Buy” rating and $10 target.

More important recent Adamis Pharmaceuticals Corp (NASDAQ:ADMP) news were published by: Marketwatch.com which released: “Adamis Pharma stock skyrockets after rival EpiPen product gets FDA approval” on June 15, 2017, also Globenewswire.com published article titled: “Adamis Pharmaceuticals Receives FDA Approval for Its Epinephrine Pre-Filled …”, Reuters.com published: “BRIEF-Adamis Pharmaceuticals gets FDA approval for co’s epinephrine pre-filled …” on June 15, 2017. More interesting news about Adamis Pharmaceuticals Corp (NASDAQ:ADMP) was released by: Seekingalpha.com and their article: “Adamis Pharmaceuticals: Strong Buy Before Huge Potential Catalyst” with publication date: June 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.